BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement

Reuters2025-01-21

Jan 21 (Reuters) - Revance Therapeutics Inc RVNC.O:

CROWN LABORATORIES AND REVANCE AMEND THE A&R MERGER AGREEMENT TO INCREASE OFFER PRICE TO $3.65 PER SHARE AND EXTEND EXISTING TENDER OFFER
INCREASED OFFER PRICE TO $3.65 PER SHARE, A $0.55 PER SHARE INCREASE
CROWN EXTENDS TENDER OFFER UNTIL FEBRUARY 4, 2025

Source text: ID:nBwbLQkd0a

Further company coverage: RVNC.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505627801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505627801","market":"us","top_or_hot":-1,"title":"BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Crown Laboratories And Revance Amend A&amp;R Merger Agreement </title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RVNC\">Revance Therapeutics Inc</a> <span>RVNC.O</span>:</p><ul><li><p>CROWN LABORATORIES AND REVANCE AMEND THE A&amp;R MERGER AGREEMENT TO INCREASE OFFER PRICE TO $3.65 PER SHARE AND EXTEND EXISTING TENDER OFFER</p></li><li><p>INCREASED OFFER PRICE TO $3.65 PER SHARE, A $0.55 PER SHARE INCREASE</p></li><li><p>CROWN EXTENDS TENDER OFFER UNTIL FEBRUARY 4, 2025</p></li></ul><p>Source text: <span>ID:nBwbLQkd0a</span></p><p>Further company coverage: <span>RVNC.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-21 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Crown Laboratories And Revance Amend A&amp;R Merger Agreement </title></head><body><p><span>Jan 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RVNC\">Revance Therapeutics Inc</a> <span>RVNC.O</span>:</p><ul><li><p>CROWN LABORATORIES AND REVANCE AMEND THE A&amp;R MERGER AGREEMENT TO INCREASE OFFER PRICE TO $3.65 PER SHARE AND EXTEND EXISTING TENDER OFFER</p></li><li><p>INCREASED OFFER PRICE TO $3.65 PER SHARE, A $0.55 PER SHARE INCREASE</p></li><li><p>CROWN EXTENDS TENDER OFFER UNTIL FEBRUARY 4, 2025</p></li></ul><p>Source text: <span>ID:nBwbLQkd0a</span></p><p>Further company coverage: <span>RVNC.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUA2ZCGQ:1","article_id":"2505627801","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505627801","pubTimestamp":1737466987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement Jan 21 (Reuters) - Revance Therapeutics Inc RVNC.O:CROWN LABORATORIES AND REVANCE AMEND THE A&R MERGER AGREEMENT TO INCREASE OFFER PRICE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","RVNC":"Revance Therapeutics Inc","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4007":"制药"},"translate_title":"简介-Crown Laboratories和Revance修改A&R合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVNC":0.9},"content_text":"BRIEF-Crown Laboratories And Revance Amend A&R Merger Agreement Jan 21 (Reuters) - Revance Therapeutics Inc RVNC.O:CROWN LABORATORIES AND REVANCE AMEND THE A&R MERGER AGREEMENT TO INCREASE OFFER PRICE TO $3.65 PER SHARE AND EXTEND EXISTING TENDER OFFERINCREASED OFFER PRICE TO $3.65 PER SHARE, A $0.55 PER SHARE INCREASECROWN EXTENDS TENDER OFFER UNTIL FEBRUARY 4, 2025Source text: ID:nBwbLQkd0aFurther company coverage: RVNC.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505627801","isCrawlerRequest":true}